Short Interest in Heron Therapeutics, Inc. (NASDAQ:HRTX) Declines By 10.6%

Heron Therapeutics, Inc. (NASDAQ:HRTX) was the recipient of a significant drop in short interest during the month of September. As of September 30th, there was short interest totalling 31,700,000 shares, a drop of 10.6% from the September 15th total of 35,440,000 shares. Based on an average trading volume of 2,200,000 shares, the days-to-cover ratio is currently 14.4 days.

Heron Therapeutics Trading Up 3.9 %

Shares of NASDAQ:HRTX traded up $0.07 during mid-day trading on Wednesday, reaching $1.87. The stock had a trading volume of 1,650,390 shares, compared to its average volume of 2,473,641. The firm has a 50 day simple moving average of $1.93 and a two-hundred day simple moving average of $2.66. Heron Therapeutics has a twelve month low of $0.50 and a twelve month high of $3.93. The firm has a market cap of $281.72 million, a PE ratio of -3.07 and a beta of 1.80.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The business had revenue of $36.02 million for the quarter, compared to the consensus estimate of $35.35 million. During the same quarter in the previous year, the business posted ($0.35) EPS. On average, equities analysts anticipate that Heron Therapeutics will post -0.1 EPS for the current fiscal year.

Institutional Trading of Heron Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. nVerses Capital LLC acquired a new position in Heron Therapeutics in the second quarter valued at about $27,000. Headlands Technologies LLC bought a new position in shares of Heron Therapeutics during the 1st quarter valued at about $30,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Heron Therapeutics in the 1st quarter valued at approximately $32,000. HB Wealth Management LLC bought a new stake in Heron Therapeutics during the 2nd quarter worth approximately $35,000. Finally, B. Riley Wealth Advisors Inc. bought a new stake in Heron Therapeutics during the 2nd quarter worth approximately $41,000. Institutional investors and hedge funds own 80.01% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 price objective on shares of Heron Therapeutics in a research note on Wednesday, September 25th.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.